Relmada Therapeutics is dedicated to improving the standard of care for central nervous system (CNS) disorders. The company focuses on advancing its ongoing Phase 3 program of REL-1017, which aims to offer a treatment for major depressive disorder (MDD).

Relmada Therapeutics, Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

COM:RELMADA

Relmada Therapeutics, Inc.

Last Close

2.75

22/11 21:00

Market Cap

84.49M

Beta: -

Volume Today

142.16K

Avg: -

Filings Not Available